Sensing of nucleic acids and cancer cells using nanostructure-SPR integrated with microfluidic chip

2016 ◽  
pp. 473-498
Author(s):  
Ji-Yen Cheng ◽  
Mousavi
Keyword(s):  
Nucleic Acids ◽  
Cancer Cells ◽  
Microfluidic Chip

627: Multitarget Gene Inhibition by Synthetic Nucleic Acids in Bladder Cancer Cells

2006 ◽  
Vol 175 (4S) ◽  
pp. 202-202 ◽  
Author(s):  
Yvonne Burmeister ◽  
Kai Kraemer ◽  
Susanne Fuessel ◽  
Matthias Kotzsch ◽  
Axel Meye ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Nucleic Acids ◽  
Cancer Cells ◽  
Bladder Cancer Cells ◽  
Gene Inhibition

scholarly journals An LED-Driven AuNPs-PDMS Microfluidic Chip and Integrated Device for the Detection of Digital Loop-Mediated Isothermal DNA Amplification

Micromachines ◽  
2020 ◽  
Vol 11 (2) ◽  
pp. 177 ◽  
Author(s):  
Zengming Zhang ◽  
Shuhao Zhao ◽  
Fei Hu ◽  
Guangpu Yang ◽  
Juan Li ◽  
...  
Keyword(s):  
Nucleic Acids ◽  
Microfluidic Chip ◽  
Cross Flow ◽  
Flow Channel ◽  
Isothermal Amplification ◽  
Fluorescent Detection ◽  
Lamp Method ◽  
Biological Studies ◽  
Micro Cavity ◽  
Integrated Device

The sensitive quantification of low-abundance nucleic acids holds importance for a range of clinical applications and biological studies. In this study, we describe a facile microfluidic chip for absolute DNA quantifications based on the digital loop-mediated isothermal amplification (digital LAMP) method. This microfluidic chip integrates a cross-flow channel for droplet generation with a micro-cavity for droplet tiling. DNA templates in the LAMP reagent were divided into ~20,000 water-in-oil droplets at the cross-flow channel. The droplets were then tiled in the micro-cavity for isothermal amplification and fluorescent detection. Different from the existing polydimethylsiloxane (PDMS) microfluidic chips, this study incorporates gold nanoparticles (AuNPs) into PDMS substrate through silica coating and dodecanol modification. The digital LAMP chip prepared by AuNPs-PDMS combines the benefits of the microstructure manufacturing performance of PDMS with the light-to-heat conversion advantages of AuNPs. Upon illumination with a near infrared (NIR) LED, the droplets were stably and efficiently heated by the AuNPs in PDMS. We further introduce an integrated device with a NIR heating unit and a fluorescent detection unit. The system could detect HBV (hepatitis B virus)-DNA at a concentration of 1 × 101 to 1 × 104 copies/μL. The LED-driven digital LAMP chip and the integrated device; therefore, demonstrate high accuracy and excellent performance for the absolute quantification of low-abundance nucleic acids, showing the advantages of integration, miniaturization, cost, and power consumption.

scholarly journals Temperature-controlled MPa-pressure ultrasonic cell manipulation in a microfluidic chip

Lab on a Chip ◽  
2015 ◽  
Vol 15 (16) ◽  
pp. 3341-3349 ◽  
Author(s):  
Mathias Ohlin ◽  
Ida Iranmanesh ◽  
Athanasia E. Christakou ◽  
Martin Wiklund
Keyword(s):  
Lung Cancer ◽  
High Pressure ◽  
Cancer Cells ◽  
Microfluidic Chip ◽  
Acoustic Streaming ◽  
Cell Manipulation ◽  
Wave Trapping ◽  
Ultrasonic Standing Wave ◽  
Temperature Controlled

We study the effect of 1 MPa-pressure ultrasonic-standing-wave trapping of cells during one hour in a fully temperature- and acoustic streaming-controlled microfluidic chip, and conclude that the viability of lung cancer cells are not affected by this high-pressure, long-term acoustophoresis treatment.

Gene therapy promises accurate, targeted administration and overcoming drug resistance in diverse cancer cells

2021 ◽  
Author(s):  
Moataz Dowaidar
Keyword(s):  
Gene Therapy ◽  
Drug Resistance ◽  
Nucleic Acid ◽  
Nucleic Acids ◽  
Clinical Research ◽  
Cancer Cells ◽  
Cationic Lipids ◽  
Target Cells ◽  
Genetic Components ◽  
Wide Range

Nucleic acid-based therapeutics such as siRNA and miRNA employ the silencing capabilities of the RNAi mechanism to affect the expression of one gene or several genes in target cells. Nucleic acid-based therapies enable accurate, targeted administration and overcoming drug resistance in diverse cancer cells. Several studies have shown that they can be utilized alongside pharmacological therapy to increase the efficacy of existing therapies. In addition, nucleic acid-based therapies have the potential to widen the spectrum of druggable targets for a range of diseases and emerge as a novel therapeutic technique for treating a number of diseases that are today untreatable. Nucleic acids are dependent on their effective distribution to target cells, which need correct complexation and encapsulation in a delivery mechanism. Although nucleic acids exist in a variety of forms and sizes, their physical and chemical commonality allow them to be loaded into a wide range of delivery vehicles. The primary biomaterials used to encapsulate genetic components were cationic lipids and polymers. Furthermore, the experiments focused particularly on effective transfection in target cells.Recent breakthroughs in NP-based RNA therapeutics have spurred a flood of clinical research, facing many challenges. In vivo, pharmacokinetics of different RNA-based medications must be researched to establish the viability and therapeutic potential of nucleic acid-based therapeutics. The U.S. Food and Drug Administration recently authorized many NP-based gene therapy. In 2019, Novartis authorized Zolgensma (onasemnogene abeparvovec-xioi) to treat spinal muscle atrophy. The first clinical research employing siRNA began in 2004 and is considered a milestone in nucleic acid-based drug development. Thirty clinical investigations have subsequently been completed. In 2018, the US FDA cleared Onpattro (Patisiran, Alnylam Pharmaceuticals) for the treatment of polyneuropathy caused by transthyretin amyloidosis.Several new generations of nucleic acid compositions employing polymer nanoparticles or liposomes are presently undergoing clinical testing. If allowed, the debut of nucleic acid-based treatments would represent a watershed event in immunotherapy. Advances in the design and development of biocompatible nanomaterials would allow us to overcome the above-mentioned problems and so show the potential to deliver nucleic acids in the treatment of a number of illnesses.

High-purity Isolation for Genotyping Rare Cancer Cells from Blood Using a Microfluidic Chip Cell Sorter

2021 ◽  
Vol 42 (1) ◽  
pp. 407-417
Author(s):  
MIO IKEDA ◽  
YASUHIRO KOH ◽  
JUN OYANAGI ◽  
SHUNSUKE TERAOKA ◽  
MASAYUKI ISHIGE ◽  
...  
Keyword(s):  
Cancer Cells ◽  
Microfluidic Chip ◽  
High Purity ◽  
Rare Cancer ◽  
Cell Sorter

scholarly journals A microfluidic chip for screening individual cancer cells via eavesdropping on autophagy-inducing crosstalk in the stroma niche

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Hacer Ezgi Karakas ◽  
Junyoung Kim ◽  
Juhee Park ◽  
Jung Min Oh ◽  
Yongjun Choi ◽  
...  
Keyword(s):  
Cancer Cells ◽  
Microfluidic Chip

MULTITARGET GENE INHIBITION BY SYNTHETIC NUCLEIC ACIDS IN BLADDER CANCER CELLS

2006 ◽  
Vol 5 (2) ◽  
pp. 38
Author(s):  
Y. Burmeister ◽  
K. Kraemer ◽  
S. Fuessel ◽  
M. Kotzsch ◽  
A. Meye ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Nucleic Acids ◽  
Cancer Cells ◽  
Bladder Cancer Cells ◽  
Gene Inhibition

Hyaluronic acid-functionalized electrospun PLGA nanofibers embedded in a microfluidic chip for cancer cell capture and culture

2017 ◽  
Vol 5 (4) ◽  
pp. 752-761 ◽  
Author(s):  
Gangwei Xu ◽  
Yulong Tan ◽  
Tiegang Xu ◽  
Di Yin ◽  
Mengyuan Wang ◽  
...  
Keyword(s):  
Hyaluronic Acid ◽  
Cancer Cells ◽  
Cancer Cell ◽  
Microfluidic Chip ◽  
Cell Capture

Hyaluronic acid-functionalized electrospun PLGA nanofibers embedded in a microfluidic chip are able to effectively capture cancer cells.

Sign in / Sign up

Export Citation Format

Share Document